ImaRx Provides Update On TUCSON Phase I/II Clinical Trial In Acute Ischemic Stroke
ImaRx Therapeutics, Inc. (Nasdaq: IMRX) provided an update on its TUCSON (Transcranial Ultrasound in Clinical SONolysis) clinical trial in patients with acute ischemic stroke. TUCSON Study Overview The TUCSON trial is a Phase I/II randomized, placebo controlled clinical trial.
More: continued here
Filed under: Clinical Trials on January 5th, 2008